$MCRB
Seres Therapeutics, Inc.

2021 Q4 Form 10-Q Financial Statement

#000095017021003937 Filed on November 10, 2021

View on sec.gov

Income Statement

Concept 2021 Q4 2021 Q3 2020 Q3
Revenue $7.221M $126.7M $1.417M
YoY Change -58.88% 8843.19% -79.85%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $20.51M $19.56M $7.550M
YoY Change 93.45% 159.11% 27.97%
% of Gross Profit
Research & Development $36.75M $39.88M $23.86M
YoY Change 47.78% 67.14% 30.27%
% of Gross Profit
Depreciation & Amortization $1.552M $1.493M $1.576M
YoY Change 3.47% -5.27% -15.99%
% of Gross Profit
Operating Expenses $56.65M $58.32M $31.41M
YoY Change 59.77% 85.66% 29.73%
Operating Profit $68.41M -$30.00M
YoY Change -328.06% 74.56%
Interest Expense -$253.0K -$154.0K -$630.0K
YoY Change 68.67% -75.56% -288.06%
% of Operating Profit -0.23%
Other Income/Expense, Net -$316.0K -$189.0K -$285.0K
YoY Change 50.48% -33.68% -136.82%
Pretax Income -$50.00M $68.22M -$30.28M
YoY Change 173.98% -325.29% 84.52%
Income Tax $0.00 $0.00
% Of Pretax Income 0.0%
Net Earnings -$50.00M $68.22M -$30.28M
YoY Change 173.98% -325.29% 84.53%
Net Earnings / Revenue -692.44% 53.83% -2136.91%
Basic Earnings Per Share $0.74 -$0.36
Diluted Earnings Per Share -$544.3K $0.72 -$0.36
COMMON SHARES
Basic Shares Outstanding 91.85M 91.76M 83.53M
Diluted Shares Outstanding 94.95M 83.53M

Balance Sheet

Concept 2021 Q4 2021 Q3 2020 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $290.7M $347.4M $297.9M
YoY Change 14.63% 16.61% 255.54%
Cash & Equivalents $180.0M $227.5M $207.3M
Short-Term Investments $110.7M $119.9M $90.60M
Other Short-Term Assets $12.92M $10.17M $6.700M
YoY Change 122.79% 51.85% 63.41%
Inventory
Prepaid Expenses
Receivables $0.00 $1.250M $3.400M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $303.6M $358.8M $308.0M
YoY Change 12.97% 16.5% 243.83%
LONG-TERM ASSETS
Property, Plant & Equipment $17.94M $17.36M $14.73M
YoY Change 29.08% 17.83% -30.39%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $495.0K $5.788M $22.40M
YoY Change -99.01% -74.16%
Other Assets $5.189M $601.0K $1.400M
YoY Change 270.64% -57.07% -6.67%
Total Long-Term Assets $51.23M $37.48M $48.20M
YoY Change -30.92% -22.24% 39.42%
TOTAL ASSETS
Total Short-Term Assets $303.6M $358.8M $308.0M
Total Long-Term Assets $51.23M $37.48M $48.20M
Total Assets $354.9M $396.3M $356.2M
YoY Change 3.48% 11.26% 186.91%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $13.74M $8.623M $6.200M
YoY Change 241.84% 39.08% 39.17%
Accrued Expenses $15.83M $13.11M $8.900M
YoY Change 34.12% 47.25% 12.66%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change -100.0%
Long-Term Debt Due $0.00 $9.345M
YoY Change
Total Short-Term Liabilities $82.26M $94.59M $45.80M
YoY Change 77.22% 106.53% 8.44%
LONG-TERM LIABILITIES
Long-Term Debt $24.64M $16.12M $25.00M
YoY Change 0.17% -35.53%
Other Long-Term Liabilities $11.50M $8.203M $97.40M
YoY Change 1046.06% -91.58% 14568.67%
Total Long-Term Liabilities $11.50M $8.203M $122.4M
YoY Change 1046.06% -93.3% 18333.73%
TOTAL LIABILITIES
Total Short-Term Liabilities $82.26M $94.59M $45.80M
Total Long-Term Liabilities $11.50M $8.203M $122.4M
Total Liabilities $223.4M $220.6M $168.1M
YoY Change 32.8% 31.2% 7.5%
SHAREHOLDERS EQUITY
Retained Earnings -$614.4M -$564.4M -$530.5M
YoY Change 11.95% 6.38% 20.34%
Common Stock $745.9M $740.1M
YoY Change 3.09%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $131.5M $175.7M $188.1M
YoY Change
Total Liabilities & Shareholders Equity $354.9M $396.3M $356.2M
YoY Change 3.48% 11.26% 186.91%

Cashflow Statement

Concept 2021 Q4 2021 Q3 2020 Q3
OPERATING ACTIVITIES
Net Income -$50.00M $68.22M -$30.28M
YoY Change 173.98% -325.29% 84.53%
Depreciation, Depletion And Amortization $1.552M $1.493M $1.576M
YoY Change 3.47% -5.27% -15.99%
Cash From Operating Activities -$51.86M $127.7M -$25.90M
YoY Change 189.74% -593.21% 41.53%
INVESTING ACTIVITIES
Capital Expenditures -$1.578M -$4.092M -$100.0K
YoY Change 689.0% 3992.0% -50.0%
Acquisitions
YoY Change
Other Investing Activities $14.76M $29.20M -$110.6M
YoY Change -119.66% -126.41% 221.51%
Cash From Investing Activities $13.19M $25.11M -$110.7M
YoY Change -117.51% -122.68% 219.94%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -780.0K 609.0K 282.3M
YoY Change -139.0% -99.78% -282400.0%
NET CHANGE
Cash From Operating Activities -51.86M 127.7M -25.90M
Cash From Investing Activities 13.19M 25.11M -110.7M
Cash From Financing Activities -780.0K 609.0K 282.3M
Net Change In Cash -39.46M 153.5M 145.7M
YoY Change -56.74% 5.33% -374.91%
FREE CASH FLOW
Cash From Operating Activities -$51.86M $127.7M -$25.90M
Capital Expenditures -$1.578M -$4.092M -$100.0K
Free Cash Flow -$50.29M $131.8M -$25.80M
YoY Change 184.1% -610.98% 42.54%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021Q3 us-gaap Preferred Stock Value
PreferredStockValue
CY2021Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2020Q3 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
us-gaap:LicenseAndServiceMember
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q3 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
us-gaap:LicenseAndServiceMember
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
us-gaap:LicenseAndServiceMember
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Entity Central Index Key
EntityCentralIndexKey
0001609809
dei Amendment Flag
AmendmentFlag
false
CY2020Q4 us-gaap Preferred Stock Value
PreferredStockValue
us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
us-gaap:LicenseAndServiceMember
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2021-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-37465
dei Entity Registrant Name
EntityRegistrantName
Seres Therapeutics, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
27-4326290
dei Entity Address Address Line1
EntityAddressAddressLine1
200 Sidney Street - 4th Floor
dei Entity Address City Or Town
EntityAddressCityOrTown
Cambridge
dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02139
dei City Area Code
CityAreaCode
617
dei Local Phone Number
LocalPhoneNumber
945-9626
dei Security12b Title
Security12bTitle
Common Stock, par value $0.001
dei Trading Symbol
TradingSymbol
MCRB
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2021Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
91847137
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
227460000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
116049000
CY2021Q3 us-gaap Short Term Investments
ShortTermInvestments
119927000
CY2020Q4 us-gaap Short Term Investments
ShortTermInvestments
137567000
CY2021Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
10174000
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5774000
CY2021Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
1250000
CY2020Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
9387000
CY2021Q3 us-gaap Assets Current
AssetsCurrent
358811000
CY2020Q4 us-gaap Assets Current
AssetsCurrent
268777000
CY2021Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
17355000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
13897000
CY2021Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
11588000
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
9041000
CY2021Q3 us-gaap Restricted Investments Noncurrent
RestrictedInvestmentsNoncurrent
2150000
CY2020Q4 us-gaap Restricted Investments Noncurrent
RestrictedInvestmentsNoncurrent
1400000
CY2021Q3 us-gaap Long Term Investments
LongTermInvestments
5788000
CY2020Q4 us-gaap Long Term Investments
LongTermInvestments
49825000
CY2021Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
601000
CY2021Q3 us-gaap Assets
Assets
396293000
CY2020Q4 us-gaap Assets
Assets
342940000
CY2021Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
8623000
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
4018000
CY2021Q3 mcrb Accrued Liabilities And Other Liabilities Current
AccruedLiabilitiesAndOtherLiabilitiesCurrent
48900000
CY2020Q4 mcrb Accrued Liabilities And Other Liabilities Current
AccruedLiabilitiesAndOtherLiabilitiesCurrent
14226000
CY2021Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
6099000
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
5115000
CY2021Q3 us-gaap Notes Payable Current
NotesPayableCurrent
9345000
CY2020Q4 us-gaap Notes Payable Current
NotesPayableCurrent
454000
CY2021Q3 mcrb Contract With Customer Liability Current Related Party
ContractWithCustomerLiabilityCurrentRelatedParty
21624000
CY2020Q4 mcrb Contract With Customer Liability Current Related Party
ContractWithCustomerLiabilityCurrentRelatedParty
22602000
CY2021Q3 us-gaap Liabilities Current
LiabilitiesCurrent
94591000
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
46415000
CY2021Q3 us-gaap Long Term Notes Payable
LongTermNotesPayable
16117000
CY2020Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
24639000
CY2021Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
12231000
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
10561000
CY2021Q3 mcrb Contract With Customer Liability Noncurrent Related Party
ContractWithCustomerLiabilityNoncurrentRelatedParty
89413000
CY2020Q4 mcrb Contract With Customer Liability Noncurrent Related Party
ContractWithCustomerLiabilityNoncurrentRelatedParty
85572000
CY2021Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
8203000
CY2020Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1003000
CY2021Q3 us-gaap Liabilities
Liabilities
220555000
CY2020Q4 us-gaap Liabilities
Liabilities
168190000
CY2021Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2021Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
91841974
CY2021Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
91841974
CY2021Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2021Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
91459239
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
91459239
CY2021Q3 us-gaap Common Stock Value
CommonStockValue
92000
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
91000
CY2021Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
739988000
CY2020Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
723482000
CY2021Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
11000
CY2020Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-47000
CY2021Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-564353000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-548776000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
175738000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
174750000
CY2021Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
396293000
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
342940000
CY2021Q3 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
26734000
CY2020Q4 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
0
CY2021Q3 us-gaap Due To Related Parties Noncurrent
DueToRelatedPartiesNoncurrent
7075000
CY2020Q4 us-gaap Due To Related Parties Noncurrent
DueToRelatedPartiesNoncurrent
0
CY2021Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
126725000
CY2020Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
80000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
136636000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
10728000
CY2021Q3 mcrb Revenue From Grant
RevenueFromGrant
0
CY2020Q3 mcrb Revenue From Grant
RevenueFromGrant
1337000
mcrb Revenue From Grant
RevenueFromGrant
1070000
mcrb Revenue From Grant
RevenueFromGrant
2907000
CY2021Q3 mcrb Revenue From Research Agreement
RevenueFromResearchAgreement
0
CY2020Q3 mcrb Revenue From Research Agreement
RevenueFromResearchAgreement
0
mcrb Revenue From Research Agreement
RevenueFromResearchAgreement
0
mcrb Revenue From Research Agreement
RevenueFromResearchAgreement
2016000
CY2021Q3 us-gaap Revenues
Revenues
126725000
CY2020Q3 us-gaap Revenues
Revenues
1417000
us-gaap Revenues
Revenues
137706000
us-gaap Revenues
Revenues
15651000
CY2021Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
39882000
CY2020Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
23861000
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
68407000
CY2020Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-29995000
us-gaap Operating Income Loss
OperatingIncomeLoss
-15061000
us-gaap Operating Income Loss
OperatingIncomeLoss
-70232000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
105139000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
65703000
CY2021Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
19563000
CY2020Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7551000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
48755000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
20180000
CY2021Q3 mcrb Profit Loss From Research Agreement Related Party
ProfitLossFromResearchAgreementRelatedParty
1127000
mcrb Profit Loss From Research Agreement Related Party
ProfitLossFromResearchAgreementRelatedParty
1127000
CY2021Q3 us-gaap Operating Expenses
OperatingExpenses
58318000
CY2020Q3 us-gaap Operating Expenses
OperatingExpenses
31412000
us-gaap Operating Expenses
OperatingExpenses
152767000
us-gaap Operating Expenses
OperatingExpenses
85883000
CY2021Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
590000
CY2020Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
100000
us-gaap Investment Income Interest
InvestmentIncomeInterest
2385000
us-gaap Investment Income Interest
InvestmentIncomeInterest
333000
CY2021Q3 us-gaap Interest Expense Debt
InterestExpenseDebt
744000
CY2020Q3 us-gaap Interest Expense Debt
InterestExpenseDebt
730000
us-gaap Interest Expense Debt
InterestExpenseDebt
2172000
us-gaap Interest Expense Debt
InterestExpenseDebt
2165000
CY2021Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-35000
CY2020Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
345000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-729000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1189000
CY2021Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-189000
CY2020Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-285000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-516000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-643000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
68218000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-30280000
us-gaap Net Income Loss
NetIncomeLoss
-15577000
us-gaap Net Income Loss
NetIncomeLoss
-70875000
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.74
CY2020Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.36
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.17
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.93
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.72
CY2020Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.36
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.17
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.93
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
91757614
CY2020Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
83531617
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
91649035
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
75914361
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
94953117
CY2020Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
83531617
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
91649035
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
75914361
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
68218000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-30280000
us-gaap Net Income Loss
NetIncomeLoss
-15577000
us-gaap Net Income Loss
NetIncomeLoss
-70875000
CY2021Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
0
CY2020Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
0
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
0
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
0
CY2021Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-1000
CY2020Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
1000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
58000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
2000
CY2021Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-1000
CY2020Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
1000
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
58000
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
2000
CY2021Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
68217000
CY2020Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-30279000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-15519000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-70873000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
-48324000
CY2020Q1 mcrb Stock Issued During Period Value At Market Equity Offerings
StockIssuedDuringPeriodValueAtMarketEquityOfferings
4178000
CY2020Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
60000
CY2020Q1 us-gaap Restricted Stock Value Shares Issued Net Of Tax Withholdings
RestrictedStockValueSharesIssuedNetOfTaxWithholdings
120000
CY2020Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
249000
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1959000
CY2020Q1 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Reclassification Adjustments Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax
-10000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-19881000
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
-61649000
CY2020Q2 mcrb Stock Issued During Period Value At Market Equity Offerings
StockIssuedDuringPeriodValueAtMarketEquityOfferings
14848000
CY2020Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
15000
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1914000
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Reclassification Adjustments Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax
11000
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-20714000
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
-65575000
CY2020Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
243748000
CY2020Q3 mcrb Stock Issued During Period To Related Party Value
StockIssuedDuringPeriodToRelatedPartyValue
19900000
CY2020Q3 mcrb Stock Issued During Period Value At Market Equity Offerings
StockIssuedDuringPeriodValueAtMarketEquityOfferings
5746000
CY2020Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
12050000
CY2020Q3 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
213000
CY2020Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2249000
CY2020Q3 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Reclassification Adjustments Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax
1000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-30280000
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
188052000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
174750000
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
372000
CY2021Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
392000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3624000
CY2021Q1 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Reclassification Adjustments Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax
32000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-35465000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
143705000
CY2021Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
586000
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5078000
CY2021Q2 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Reclassification Adjustments Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax
27000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-48330000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
101066000
CY2021Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
174000
CY2021Q3 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
435000
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5846000
CY2021Q3 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Reclassification Adjustments Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax
-1000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
68218000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
175738000
us-gaap Net Income Loss
NetIncomeLoss
-15577000
us-gaap Net Income Loss
NetIncomeLoss
-70875000
us-gaap Share Based Compensation
ShareBasedCompensation
14548000
us-gaap Share Based Compensation
ShareBasedCompensation
6122000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
4395000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
5069000
mcrb Non Cash Operating Lease Cost
NonCashOperatingLeaseCost
2292000
mcrb Non Cash Operating Lease Cost
NonCashOperatingLeaseCost
1693000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-2097000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
105000
mcrb Noncash Interest Expense
NoncashInterestExpense
368000
mcrb Noncash Interest Expense
NoncashInterestExpense
329000
mcrb Profit Loss From Research Agreement Related Party
ProfitLossFromResearchAgreementRelatedParty
1127000
mcrb Increase Decrease In Prepaid Expenses And Other Current And Long Term Assets
IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAndLongTermAssets
-5001000
mcrb Increase Decrease In Prepaid Expenses And Other Current And Long Term Assets
IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAndLongTermAssets
-3054000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-8137000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
1608000
mcrb Increase Decrease In Contract With Customer Liability Related Party
IncreaseDecreaseInContractWithCustomerLiabilityRelatedParty
2863000
mcrb Increase Decrease In Contract With Customer Liability Related Party
IncreaseDecreaseInContractWithCustomerLiabilityRelatedParty
-11917000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
4781000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1032000
mcrb Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-2185000
mcrb Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-3288000
mcrb Increase Decrease In Accrued Expenses And Other Current And Long Term Liabilities
IncreaseDecreaseInAccruedExpensesAndOtherCurrentAndLongTermLiabilities
42960000
mcrb Increase Decrease In Accrued Expenses And Other Current And Long Term Liabilities
IncreaseDecreaseInAccruedExpensesAndOtherCurrentAndLongTermLiabilities
919000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
58551000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-75683000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
365000
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
66342000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
7988000
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
125995000
us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
125982000
us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
42804000
mcrb Payments For Restricted Investments
PaymentsForRestrictedInvestments
750000
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
mcrb Entity Incorporation Month And Year Of Incorporation
EntityIncorporationMonthAndYearOfIncorporation
2010-10
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
50902000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-83556000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
244020000
mcrb Proceeds From Securities Purchase Agreement Net Of Issuance Costs Related Party
ProceedsFromSecuritiesPurchaseAgreementNetOfIssuanceCostsRelatedParty
20000000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1131000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
12065000
mcrb Proceeds From Issuance Of Common Stock And Restricted Common Stock
ProceedsFromIssuanceOfCommonStockAndRestrictedCommonStock
120000
mcrb Proceeds From At The Market Equity Offering Net Of Commissions
ProceedsFromAtTheMarketEquityOfferingNetOfCommissions
24772000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
827000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
462000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1958000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
301439000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
111411000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
142200000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
116049000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
65126000
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
227460000
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
207326000
us-gaap Interest Paid Net
InterestPaidNet
1836000
us-gaap Interest Paid Net
InterestPaidNet
1843000
mcrb Issuance Costs From Public Offering Included In Accounts Payable And Accrued Payable
IssuanceCostsFromPublicOfferingIncludedInAccountsPayableAndAccruedPayable
272000
mcrb Securities Purchase Agreement Issuance Costs Included In Accounts Payable And Accrued Expenses Related Party
SecuritiesPurchaseAgreementIssuanceCostsIncludedInAccountsPayableAndAccruedExpensesRelatedParty
100000
mcrb Proceeds From Exercise Of Stock Options In Prepaid Expenses And Other Current Assets
ProceedsFromExerciseOfStockOptionsInPrepaidExpensesAndOtherCurrentAssets
61000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
4839000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
316000
mcrb Accrued Expenses And Other Current And Long Term Liabilities Related Party Amounts
AccruedExpensesAndOtherCurrentAndLongTermLiabilitiesRelatedPartyAmounts
33809000
CY2020 mcrb Accrued Expenses And Other Current And Long Term Liabilities Related Party Amounts
AccruedExpensesAndOtherCurrentAndLongTermLiabilitiesRelatedPartyAmounts
0
CY2021Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-564353000
CY2021Q3 mcrb Cash Cash Equivalents And Short And Long Term Investments
CashCashEquivalentsAndShortAndLongTermInvestments
353175000
us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Use of Estimates</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenue and expenses during the reporting periods. In the condensed consolidated financial statements, the Company uses estimates and assumptions related to revenue recognition and the accrual of research and development expenses. Estimates are periodically reviewed in light of changes in circumstances, facts and experience.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The full extent to which the COVID-19 pandemic will directly or indirectly impact the Company’s business, results of operations and financial condition, including revenue, operating expenses, clinical trials and employee-related amounts, will depend on future developments that are highly uncertain, including new information that may emerge concerning COVID-19 and the actions taken to contain it or treat its impact and the economic impact on local, regional, national and international markets. We have made estimates of the impact of COVID-19 within our financial statements and there may be changes to those estimates in future periods. Actual results could differ from the Company’s estimates.</span></p>
CY2021Q3 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0
CY2021Q3 us-gaap Fair Value Assets Level2 To Level1 Transfers Amount
FairValueAssetsLevel2ToLevel1TransfersAmount
0
CY2020Q3 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0
CY2020Q3 us-gaap Fair Value Assets Level2 To Level1 Transfers Amount
FairValueAssetsLevel2ToLevel1TransfersAmount
0
CY2021Q3 us-gaap Restricted Investments Noncurrent
RestrictedInvestmentsNoncurrent
2150000
CY2020Q4 us-gaap Restricted Investments Noncurrent
RestrictedInvestmentsNoncurrent
1400000
CY2021Q3 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
125704000
CY2021Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
19000
CY2021Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
8000
CY2021Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
125715000
CY2020Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
187439000
CY2020Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
14000
CY2020Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
61000
CY2020Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
187392000
mcrb Cash Equivalents Original Maturity Maximum Period
CashEquivalentsOriginalMaturityMaximumPeriod
P90D
CY2021Q3 us-gaap Restricted Investments Noncurrent
RestrictedInvestmentsNoncurrent
2150000
CY2020Q4 us-gaap Restricted Investments Noncurrent
RestrictedInvestmentsNoncurrent
1400000
CY2020Q4 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
49825000
CY2021Q3 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
125704000
CY2021Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
125715000
CY2020Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
187439000
CY2020Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
187392000
CY2021Q3 us-gaap Available For Sale Securities Debt Maturities Within One Year Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
119915000
CY2021Q3 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
119927000
CY2020Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
137588000
CY2020Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
137567000
CY2021Q3 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost
5789000
CY2021Q3 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
5788000
CY2020Q4 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost
49851000
CY2021Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
56071000
CY2020Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
48217000
CY2021Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
38716000
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
34320000
CY2021Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
17355000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
13897000
CY2021Q3 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1493000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
4395000
CY2020Q3 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1576000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
5069000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
75914361
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
2825431
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
22.27
CY2021Q3 mcrb Accrued Development And Clinical Manufacturing Costs Current
AccruedDevelopmentAndClinicalManufacturingCostsCurrent
13530000
CY2020Q4 mcrb Accrued Development And Clinical Manufacturing Costs Current
AccruedDevelopmentAndClinicalManufacturingCostsCurrent
6339000
CY2021Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
7006000
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
6734000
CY2021Q3 mcrb Accrued Liability Related To2021 License Agreement Current
AccruedLiabilityRelatedTo2021LicenseAgreementCurrent
26734000
CY2021Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1630000
CY2020Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1153000
CY2021Q3 mcrb Accrued Liabilities And Other Liabilities Current
AccruedLiabilitiesAndOtherLiabilitiesCurrent
48900000
CY2020Q4 mcrb Accrued Liabilities And Other Liabilities Current
AccruedLiabilitiesAndOtherLiabilitiesCurrent
14226000
CY2021Q3 us-gaap Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year
LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
949000
CY2021Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
11970000
CY2021Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
12081000
CY2021Q3 us-gaap Long Term Debt
LongTermDebt
25000000
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
10037130
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
9.54
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y10M13D
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
156627000
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
281668
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
3.89
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
1677450
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
12.11
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
10903443
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
11.28
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y6M14D
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
19879702000
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
5197692
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
8.34
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y2M26D
CY2021Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
10950342000
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
10.08
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
17.89
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
18.12
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
3.03
CY2021Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5846000
CY2020Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2249000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
14548000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6122000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
68218000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-30280000
us-gaap Net Income Loss
NetIncomeLoss
-15577000
us-gaap Net Income Loss
NetIncomeLoss
-70875000
CY2021Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
68218000
CY2020Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-30280000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-15577000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-70875000
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
91757614
CY2020Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
83531617
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
91649035
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.74
CY2020Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.36
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.17
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.93
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
68218000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-30280000
us-gaap Net Income Loss
NetIncomeLoss
-15577000
us-gaap Net Income Loss
NetIncomeLoss
-70875000
CY2021Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
68218000
CY2020Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-30280000
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-15577000
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-70875000
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
91757614
CY2020Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
83531617
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
91649035
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
75914361
CY2021Q3 mcrb Incremental Common Shares Attributable To Dilutive Effect Of Stock Options To Purchase Common Stock
IncrementalCommonSharesAttributableToDilutiveEffectOfStockOptionsToPurchaseCommonStock
3186762
CY2021Q3 mcrb Incremental Common Shares Attributable To Dilutive Effect Of Unvested Restricted Stock Units
IncrementalCommonSharesAttributableToDilutiveEffectOfUnvestedRestrictedStockUnits
8741
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
94953117
CY2020Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
83531617
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
91649035
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
75914361
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.72
CY2020Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.36
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.17
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.93
CY2016Q1 mcrb Collaborative Arrangement Upfront License Fee Received
CollaborativeArrangementUpfrontLicenseFeeReceived
120000000
CY2021Q3 mcrb Contract With Customer Liability Revenue Recognized With Related Party
ContractWithCustomerLiabilityRevenueRecognizedWithRelatedParty
-4618000
mcrb Contract With Customer Liability Revenue Recognized With Related Party
ContractWithCustomerLiabilityRevenueRecognizedWithRelatedParty
4028000
mcrb Contract With Customer Liability Revenue Recognized With Related Party
ContractWithCustomerLiabilityRevenueRecognizedWithRelatedParty
11837000
CY2021Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2020Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2021Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2020Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2021Q3 us-gaap Income Tax Examination Penalties And Interest Accrued
IncomeTaxExaminationPenaltiesAndInterestAccrued
0
CY2020Q4 us-gaap Income Tax Examination Penalties And Interest Accrued
IncomeTaxExaminationPenaltiesAndInterestAccrued
0

Files In Submission

Name View Source Status
0000950170-21-003937-index-headers.html Edgar Link pending
0000950170-21-003937-index.html Edgar Link pending
0000950170-21-003937.txt Edgar Link pending
0000950170-21-003937-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
img49713950_0.jpg Edgar Link pending
mcrb-20210930.htm Edgar Link pending
mcrb-20210930.xsd Edgar Link pending
mcrb-20210930_cal.xml Edgar Link unprocessable
mcrb-20210930_def.xml Edgar Link unprocessable
mcrb-20210930_htm.xml Edgar Link completed
mcrb-20210930_lab.xml Edgar Link unprocessable
mcrb-20210930_pre.xml Edgar Link unprocessable
mcrb-ex10_1.htm Edgar Link pending
mcrb-ex10_2.htm Edgar Link pending
mcrb-ex10_3.htm Edgar Link pending
mcrb-ex31_1.htm Edgar Link pending
mcrb-ex31_2.htm Edgar Link pending
mcrb-ex32_1.htm Edgar Link pending
mcrb-ex32_2.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending